|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Leptin, cardiovascular diseases and type 2 diabetes mellitus显示文摘Leptin,经由胃口抑制在食物吸入的控制被含有的 adipokine,可以也刺激氧化应力,发炎,血栓,动脉的僵硬, angiogenesis 和 atherogenesis。这些导致 leptin 的效果可以预先安排到心血管的疾病的发展。在现在的评论,我们讨论与两个的存在,严厉或预后连接 leptin 层次的证据冠的动脉疾病和非心脏的脉管的疾病象中风那样,颈动脉动脉疾病,外部动脉疾病(垫)和象与长期的肾疾病( CKD )和类型一样的腹的大动脉的动脉瘤( AAA ) 2 糖尿病 mellitus ( T2DM )。Leptin 层次断然与存在,严厉,程度和冠的动脉粥样硬化以及与存在,严厉和 ischemic 和出血性的击的差的临床的结果的损害复杂性被联系了。但是冲突结果也存在。而且, leptin 被报导独立地预言普通颈动脉 intima 媒介厚度和颈动脉匾不稳定性。在 hyperleptinemia 和垫之间的一个连接被报导了,而有限数据在在 leptin 和 AAA 之间的潜在的协会上是可得到的。提高的 leptin 集中也象与胰岛素抵抗一样与 CKD 发生和前进有关, T2DM,微 -- 并且 macrovascular 糖尿病患者复杂并发症。Statins 和 antidiabetic 药(包括的 sitagliptin, metformin, pioglitazone, liraglutide 和 empagliflozin ) 可以影响 leptin 层次。进一步的研究被需要建立潜在的使用(如果任何) 是的 leptin 在这些疾病的一个治疗学的目标。 | Niki KATSIKI Dimitri P MIKHAILIDIS Maciej BANACH | 2018 | Acta Pharmacologica Sinica2018，39，7： | 41 |
| 2 | ESVS指南:颈动脉狭窄有创性治疗的适应证和技术显示文摘欧洲血管外科学会召集颈动脉疾病领域的专家制定了关于颈动脉疾病有创性治疗的最新指南。根据证据级别对推荐意见进行分级。对于狭窄程度〉50%的有症状患者,如果围手术期卒中/死亡发生率〈6%,则推荐行颈动脉内膜切除术(carotid endarterectomy,CEA)(A级推荐),最好在患者最近发作的2周内进行(A级推荐)。对于狭窄程度为70%~99%并且年龄在75岁以下的男性无症状患者,如果围手术期卒中/死亡发生率〈3%,也推荐行CEA(A级推荐)。女性无症状患者从CEA中获得的益处明显不如男性患者(A级推荐)。因此,只有年龄较小的合适的女性患者才考虑行CEA(A级推荐)。颈动脉补片血管成形术优于直接缝合(A级推荐)。在CEA术前、术中和术后均应给予阿司匹林(75~325medd)和他汀类药物治疗(A级推荐)。颈动脉支架置入术(carotid artery stenting,CAS)仅适用于CEA高危患者,并且应在围手术期卒中,死亡发生率较低的大型中心或是在随机对照试验中进行(C级推荐)。在CAS治疗的同时,应使用阿司匹林+氯吡格雷双重抗血小板治疗(A级推荐)。使用颈动脉保护装置可能有益(C级推荐)。 | C.D. Liapis P.R.F. Bell D. Mikhailidis J. Sixenius A. Nicolaides J. Femandes e Fermndes G. Biasi L. Norgren 无 尧瑶(译) 兰青(译) | 2009 | 国际脑血管病杂志2009，17，5： | 34 |
| 3 | Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome显示文摘AIM: To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis(NASH). At present there is no effective treatment for non-alcoholic fatty liver disease or its advanced form NASH.METHODS: This prospective study included 20 biopsy proven patients with NASH, metabolic syndrome(Met S) and dyslipidaemia. Biochemical parameters of the blood of the patients and an ultrasonography of the liver were performed at baseline. Then patients receivedlifestyle advice and were treated for a 12 mo period with rosuvastatin(10 mg/d) monotherapy. Patients were re-evaluated during the study at 3 mo intervals, during which biochemical parameters of the blood were measured including liver enzymes. A repeat biopsy and ultrasonography of the liver were performed at the end of the study in all 20 patients. Changes in liver enzymes, fasting plasma glucose, serum creatinine, serum uric acid(SUA), high sensitivity C reactive protein(hs CRP) and lipid profile were assessed every 3 mo. The primary endpoint was the resolution of NASH and the secondary endpoints were the changes in liver enzyme and lipid values.RESULTS: The repeat liver biopsy and ultrasonography showed complete resolution of NASH in 19 patients, while the 20 th, which had no improvement but no deterioration either, developed arterial hypertension and substantial rise in triglyceride levels during the study, probably due to changes in lifestyle including alcohol abuse. Serum alanine transaminase, aspartate transaminase, and γ-glutamyl transpeptidase were normalised by the 3rd treatment month(ANOVA P < 0.001), while alkaline phosphatase activities by the 6th treatment month(ANOVA, P = 0.01). Fasting plasma glucose and glycated haemoglobin were significantly reduced(P < 0.001). Lipid values were normalised by the 3rd treatment month. No patient had Met S by the 9th treatment month. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed solely to rosuvastatin treatment. A limitation of the study is the absence of a control group.CONCLUSION: These findings suggest that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve Met S within 12 mo. These effects and the reduction of fasting plasma glucose and SUA levels may reduce the risk of vascular and liver morbidity and mortality in NASH patients. These findings need confirmation in larger studies. | Konstantinos Kargiotis Vasilios G Athyros Olga Giouleme Niki Katsiki Evangelia Katsiki Panagiotis Anagnostis Chrysoula Boutari Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis | 2015 | World Journal of Gastroenterology2015，21，25： | 18 |
| 4 | 欧洲血管外科学会指南:第二部分——颈动脉狭窄患者的诊断和检查显示文摘在此,我们呈献颈动脉狭窄患者脑血管事件二级预防的欧洲血管外科学会指南,包括降脂治疗、抗血小板治疗以及其他危险因素控制。这些推荐均基于现有的临床试验证据。对颈动脉病患者需要采取积极的预防性治疗。我们还讨论了颈动脉狭窄的诊断和分级。 | Christos D. Liapis Sir Peter F. Bell Dimitri P. Mikhailidis Juharli Sivenius Andrew Nicolaides Jose Femandes e Fernandes Giorgio Biasi Ears Norgrer 赵颖(译) 谭泽锋(译) 徐安定(译) | 2011 | 国际脑血管病杂志2011，19，7： | 9 |
| 5 | 欧洲血管外科学会指南:第1部分——颈动脉狭窄患者的预防显示文摘在此,我们呈献颈动脉狭窄患者脑血管事件二级预防的欧洲血管外科学会指南,包括降脂治疗、抗血小板治疗以及其他危险因素控制。这些推荐均基于现有的临床试验证据。对颈动脉疾病患者需要采取积极的预防性治疗。我们还讨论了颈动脉狭窄的诊断和分级。 | Christos D. Liapis Sir Peter F. Bell Dimitri P. Mikhailidis Juhani Sivenius Andrew Nicolaides Jose Femandes e Fernandes Giorgio Biasi Lars Norgren 董大伟(译) 刘小艳(译) 徐安定(译) | 2011 | 国际脑血管病杂志2011，19，6： | 7 |
| 6 | Mean Platelet Volume: A Link Between Thrombosis and Inflammation?显示文摘 | Armen Yuri Gasparyan Lilit Ayvazyan Dimitri P. Mikhailidis George D. Kitas | 2011 | Current Pharmaceutical Design2011，，1： | 3 |
| 7 | A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors 显示文摘 | CHENG K S MIKHAILIDIS D P HAMITON G | 2002 | Cardiovasc Res2002，54，3： | 3 |
| 8 | Gene therapy and erectile dysfunction: the current status显示文摘为可勃起的机能障碍(编辑) 的当前的可得到的处理选择是有效的然而并非没有失败或副作用。尽管 phosphodiesterasetype 的发展 5 (PDE5 ) 禁止者(即 sildenafil, tadalafil 和 vardenafil ) 革命化了编辑的治疗,这些口头的药要求按需的存取并且不作为与糖尿病、前列腺切除术以后、严重的 veno 闭塞的疾病状态有关的有效 intreating 编辑。在编辑的治疗的改进依赖于理解人的肉体的光滑的肌肉音调并且在相关分子的目标的鉴定上的规定。未来编辑治疗可能考虑象基因治疗那样的分子的技术的申请。作为一个潜在的治疗学的工具,没有影响休息阴茎功能,基因治疗可能“在需求上”为 alteringintracavernous 压力提供一个有效、特定的工具。然而,基因治疗的安全仍然是一个主要障碍在作为一个主流的处理被接受让编辑基因治疗目的在编辑治好内在的条件前克服,包括纤维变性。而且,基因治疗可能帮助由改进阴茎氮的 oxidebioactivity 延长 PDE5 禁止者的功效。因为它的地点和可接近性,处于松驰的状态的低阴茎循环流动和 endotheliallined (花格平顶) 的存在空格,把基因治疗用于阴茎是可行的。这评论在编辑的管理提供基因治疗的当前的角色的简短卓见。 | David H. W. Lau Sashi S. Kommu Emad J. Siddiqui Cecil S. Thompson Robert J. Morgan Dimitri P. Mikhailidis Faiz H. Mumtaz | 2007 | Asian Journal of Andrology2007，9，1： | 2 |
| 9 | The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification显示文摘 | Konstantinos Tziomalos Vasilios G Athyros Asterios Karagiannis Dimitri P Mikhailidis | 2010 | Current Opinion in Cardiology2010，，4： | 2 |
| 10 | Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis显示文摘 | Vasilios G Athyros Konstantinos Tziomalos Thomas D Gossios Theodora Griva Panagiotis Anagnostis Konstantinos Kargiotis Efstathios D Pagourelias Eleni Theocharidou Asterios Karagiannis Dimitri P Mikhailidis | 2010 | The Lancet2010，，9756： | 2 |
| 11 | Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease:an update显示文摘 | Vasilios G Athyros Konstantinos Tziomalos Niki Katsiki Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis | 2015 | World Journal of Gastroenterology2015，，22： | 2 |
| 12 | Smoking and erectile dysfunction显示文摘 | Jeremy J Y Mikhailidis D P | 1998 | J Roy Soc Health1998，118，： | 1 |
| 13 | Assessment and clinical relevance of non-fasting and postprandial triglycerides:an expert panel statement显示文摘 | Kolovou GD Mikhailidis DP Kovar J | 2011 | Curr Vasc Pharmacol2011，9，3： | 1 |
| 14 | Statin-fibrate combination:therapy for hyperlipidemia:a review显示文摘 | WIERZBICKI AS MIKHAILIDIS DP WRAY R | 2003 | Curr Med Res Opin2003，19，3： | 1 |
| 15 | The role of serotonin (5-hydroxytryptaminelA and 1B) receptors in prostate cancer cell proliferation显示文摘 | Siddiqui E J Shabbir M Mikhailidis DP | 2006 | J Urol2006，176，41： | 1 |
| 16 | Early vascular benefits ofstatin therapy 显示文摘 | Tsiara S Elisaf M Mikhailidis DP | 2003 | Curr Med Res Opin2003，19，8： | 1 |
| 17 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study显示文摘 | T. D. Filippatos D. N. Kiortsis E. N. Liberopoulos M. Georgoula D. P. Mikhailidis M. S. Elisaf | 2005 | Current Medical Research and Opinion?2005，，12： | 1 |
| 18 | The effect of ethanol on platelet function and vascular prostanoids显示文摘 | Mikhailidis DP Barradas MA Jeremy JY | 1990 | Alcohol1990，7，2： | 1 |
| 19 | Correlation between serum gamma-glutamyl transferase activity and the platelet count显示文摘 | Bolodeoku JA Ganotakis ES Mikhailidis DP | | 0，，05： | 1 |
| 20 | Acute panereatitis in pregnancy:an overview显示文摘 | Papadakis EP Sarigianni M Mikhailidis DP | 2011 | European Journal of Obstetrics&Amp Gy-necology and Reproductive Biology2011，，02： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员